TickerFacts.

Rocket One Inc. (RKTO): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2022-12-31, 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$5.95M
Year ended 2025-12-31
$6.42M
Trailing 12 months to 2026-06-30
$7.35M2018-12-31: $785.3K2019-12-31: $2.03M2020-12-31: $2.28M2021-12-31: $7.35M2022-12-31: $4.93M2023-12-31: $3.74M2024-12-31: $3.25M2025-12-31: $5.95M$5.95M
2018-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$5.95M+83.0%2026-03-27, From 2025-01-01
2024-12-31$3.25M-13.1%2026-03-27, From 2024-01-01
2023-12-31$3.74Mn/c2025-03-28, From 2023-01-01
2022-12-31$4.93Mn/c2024-03-28, From 2022-01-01
2021-12-31$7.35M+222.4%2023-03-31, From 2021-01-01
2020-12-31$2.28M+12.7%2022-03-30, From 2020-01-01
2019-12-31$2.03M+157.9%2021-03-16, From 2019-01-01
2018-12-31$785.3Kn/a2020-03-02, From 2018-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Rocket One Inc. (RKTO)2025-12-31$5.95M+83.0%
Silo Pharma, Inc. (SILO)2025-12-31$2.16M-8.8%
Oncolytics Biotech Inc (ONCY)2025-12-31$13.31M-13.8%
Acurx Pharmaceuticals, Inc. (ACXP)2025-12-31$1.83M-66.1%
Ensysce Biosciences, Inc. (ENSC)2025-12-31$10.38M+43.7%
Processa Pharmaceuticals, Inc. (PCSA)2025-12-31$7.81M+7.4%
Dermata Therapeutics, Inc. (DRMA)2025-12-31$2.93M-64.3%
Telomir Pharmaceuticals, Inc. (TELO)2025-12-31$2.44M+9.0%
Matinas BioPharma Holdings, Inc. (MTNB)2025-12-31$85.0K-99.3%

Compare RKTO, SILO, ONCY, ACXP side by side · Screen every company in Pharmaceutical Preparations ↗